Integrating AI with care: FDA reveals focus areas for forthcoming guidance on AI products
Posted:
The FDA is focusing on integrating #AI with care, outlining key areas for forthcoming guidance on AI products. As AI technology expands, it's crucial to ensure safe implementation.
In Bold Insight latest blog, Stephanie Wiltman breaks down the FDA's focus areas and how they'll shape the future of AI in healthcare.
Currently more than 50 per cent of women are diagnosed with ovarian cancer at an advanced stage when fewer treatment options are available. A specialist medical tampon could be used to help diagnose ovarian cancer earlier, researchers believe.
Read more here.
A clinical trial into puberty blockers for children has been paused after the medicines regulator warned it should have a minimum age limit of 14 because of the “unquantified risk” of “long-term biological harms”.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us